Cost and utilization impact of a clinical pathway for patients undergoing pancreaticoduodenectomy

被引:163
|
作者
Porter, GA [1 ]
Pisters, PWT [1 ]
Mansyur, C [1 ]
Bisanz, A [1 ]
Reyna, K [1 ]
Stanford, P [1 ]
Lee, JE [1 ]
Evans, DB [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
关键词
pancreaticoduodenectomy; costs; clinical pathway; resource utilization;
D O I
10.1007/s10434-000-0484-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:When implemented in several common surgical procedures, clinical pathways have been reported to reduce costs and resource utilization, while maintaining or improving patient care. However, then is little data to support their use in more complex surgery. The objective of this study was to determine the effects of clinical pathway implementation in patients undergoing elective pancreaticoduodenectomy (PD) on cost and resource utilization. Methods: Outcome data from before and after the development of a clinical pathway were analyzed. The clinical pathway standardized the preoperative outpatient care, critical care, and postoperative floor care of patients who underwent PD. An independent department determined total costs for each patient, which included all hospital and physician costs, in a blinded review. Outcomes that were examined included perioperative mortality, postoperative morbidity, length of stay, readmissions, and postoperative clinic visits. Results: From January, 1996 to December, 1998, 148 consecutive patients underwent PD or total pancreatectomy; 68 before pathway development (PrePath) and 80 after pathway implementation (PostPath). There were no significant differences in patient demographics, comorbid conditions, underlying diagnosis, or use of neoadjuvant therapy between the two groups. Mean total costs were significantly reduced in PostPath patients compared with PrePath patients ($36,627 vs. $47,515; P = .003). Similarly, mean length of hospital stay was also significantly reduced in PostPath patients (13.5 vs. 16.4 days; P = .001). The total cost differences could not be attributed solely to differences in room and board costs. Cost and length-of-stay differences remained when outliers were excluded from the analysis. Despite these findings, there were no significant differences between PrePath and PostPath patients in terms of perioperative mortality (3% vs, 1%), readmissions within 1 month of discharge (15% vs. 11%), or mean number of clinic visits within 90 days of discharge (3.3 vs. 3.3 visits). Conclusions: The establishment of a clinical pathway for PD patients dramatically reduced costs and resource utilization without any apparent detrimental effect on quality of patient care. These findings support the implementation of clinical pathways for PD patients, as well as investigation into pathway care for other complex surgical procedures.
引用
收藏
页码:484 / 489
页数:6
相关论文
共 50 条
  • [41] Quality of life in patients with pancreatic ductal adenocarcinoma undergoing pancreaticoduodenectomy
    Laitinen, Ismo
    Sand, Juhani
    Peromaa, Pipsa
    Nordback, Isto
    Laukkarinen, Johanna
    PANCREATOLOGY, 2017, 17 (03) : 445 - 450
  • [42] New score for prediction of morbidity in patients undergoing open pancreaticoduodenectomy
    Chen, Lian
    Peng, Li
    Wang, Chao
    Li, Sheng-Chao
    Zhang, Meng
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (03)
  • [43] Clinical impact of preoperative acute pancreatitis in patients who undergo pancreaticoduodenectomy for periampullary tumors
    Yong-Hua Chen
    Si-Ming Xie
    Hao Zhang
    Chun-Lu Tan
    Neng-Wen Ke
    Gang Mai
    Xu-Bao Liu
    World Journal of Gastroenterology, 2015, (22) : 6937 - 6943
  • [44] Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP)
    Zheng, Richard
    Lam, Edwin
    Altshuler, Peter
    Crutcher, Madison
    Lavu, Harish
    Yeo, Charles J.
    Stickle, Douglas
    Leiby, Benjamin
    Kraft, Walter K.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2024, 62 (07) : 319 - 325
  • [45] Pylorus-Preserving Pancreaticoduodenectomy in Patients Undergoing Chronic Hemodialysis
    Uchida, Hiroki
    Shibata, Kohei
    Kai, Seiichiro
    Iwaki, Kentaro
    Ohta, Masayuki
    Kitano, Seigo
    SURGERY TODAY, 2008, 38 (12) : 1152 - 1154
  • [46] Outcome following pancreaticoduodenectomy in patients undergoing preoperative biliary drainage
    Srivastava, S
    Sikora, SS
    Kumar, A
    Saxena, R
    Kapoor, VK
    DIGESTIVE SURGERY, 2001, 18 (05) : 381 - 386
  • [47] Extracorporeal photopheresis for graft versus host disease: Identifying a clinical pathway and associated resource utilization
    Yerrabothala, Swaroopa
    Talebian, Laleh
    Klinker, Karen
    Hickman, Joshua
    Hill, John M.
    Hayes, Christi
    Lowrey, Christopher
    Szczepiorkowski, Zbigniew M.
    Meehan, Kenneth R.
    JOURNAL OF CLINICAL APHERESIS, 2018, 33 (03) : 310 - 315
  • [48] Pancreaticoduodenectomy versus pylorus-preserving pancreaticoduodenectomy: the clinical impact of a new surgical procedure; pylorus-resecting pancreaticoduodenectomy
    Kawai, Manabu
    Yamaue, Hiroki
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2011, 18 (06) : 755 - 761
  • [49] Impact of Surgeon and Hospital Volume on Mortality, Length of Stay, and Cost of Pancreaticoduodenectomy
    Laura M. Enomoto
    Niraj J. Gusani
    Peter W. Dillon
    Christopher S. Hollenbeak
    Journal of Gastrointestinal Surgery, 2014, 18 : 690 - 700
  • [50] Impact of Surgeon and Hospital Volume on Mortality, Length of Stay, and Cost of Pancreaticoduodenectomy
    Enomoto, Laura M.
    Gusani, Niraj J.
    Dillon, Peter W.
    Hollenbeak, Christopher S.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2014, 18 (04) : 690 - 700